5 Takeaways From The Novartis FCA Settlement

Law360, New York (November 1, 2015, 9:26 AM EST) -- Gary Giampetruzzi

Terra Reynolds During an analyst call on Oct. 27, 2015, Novartis AG’s CEO Joe Jimenez announced that its U.S. affiliate, Novartis Pharmaceuticals Corporation reached a settlement in principle under which it will pay $390 million to the U.S. Department of Justice and certain states to resolve civil claims that the company induced specialty pharmacies to boost prescriptions for Novartis drugs by paying kickbacks in the form of rebates.[1]

The claims against Novartis stemmed from a whistleblower lawsuit brought by a former Novartis employee in...
To view the full article, register now.